Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

The summer concert season is so close you can hear it coming around the corner. Our favorite time of year around these parts officially launches when Yungblud opens the season May 1 at Michigan ...

So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will spend $7 billion to acquire privately held Kelonia Therapeutics and its KLN-1010 CAR-T gene therapy drug ...

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Add Yahoo as a preferred source to see more of our stories on Google. April 19 (Reuters) - U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, ...

Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...

Eli Lilly LLY0.69%increase; green up pointing triangle has agreed to buy clinical-stage company Centessa Pharmaceuticals CNTA-0.13%decrease; red down pointing triangle for an initial payment of about ...

Since investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of the Indianapolis drugmaker has dropped by more than 7%. Creating the stir ...

Eli Lilly and Co. is spending as much as $1.8 billion to upgrade its near-downtown Indianapolis research and manufacturing operations over the next several years. The investment, shared with IBJ this ...